NOVO.B.DK

443.1

-1.47%↓

COLO.B.DK

601.8

-0.36%↓

GMAB.DK

1,371

+0.51%↑

ZEAL.DK

364.5

-2.49%↓

AMBUB.DK

97.2

-0.36%↓

NOVO.B.DK

443.1

-1.47%↓

COLO.B.DK

601.8

-0.36%↓

GMAB.DK

1,371

+0.51%↑

ZEAL.DK

364.5

-2.49%↓

AMBUB.DK

97.2

-0.36%↓

NOVO.B.DK

443.1

-1.47%↓

COLO.B.DK

601.8

-0.36%↓

GMAB.DK

1,371

+0.51%↑

ZEAL.DK

364.5

-2.49%↓

AMBUB.DK

97.2

-0.36%↓

NOVO.B.DK

443.1

-1.47%↓

COLO.B.DK

601.8

-0.36%↓

GMAB.DK

1,371

+0.51%↑

ZEAL.DK

364.5

-2.49%↓

AMBUB.DK

97.2

-0.36%↓

NOVO.B.DK

443.1

-1.47%↓

COLO.B.DK

601.8

-0.36%↓

GMAB.DK

1,371

+0.51%↑

ZEAL.DK

364.5

-2.49%↓

AMBUB.DK

97.2

-0.36%↓

Search

H Lundbeck A-S

Затворен

34.06 -3.79

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

32.86

Максимум

35.4

Ключови измерители

By Trading Economics

Приходи

562M

1.2B

Продажби

694M

6.2B

P/E

Средно за сектора

10.602

39.564

EPS

1.53

Дивидентна доходност

2.61

Марж на печалбата

18.476

Служители

5,700

EBITDA

811M

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

2.61%

2.40%

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-3B

34B

Предишно отваряне

37.85

Предишно затваряне

34.06

H Lundbeck A-S Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

9.07.2025 г., 15:46 ч. UTC

Значими двигатели на пазара

BitMine Shares Fall After Closing of $250 Million Private Placement

9.07.2025 г., 23:44 ч. UTC

Пазарно говорене

Gold Edges Higher Amid U.S. Tariff Concerns -- Market Talk

9.07.2025 г., 23:42 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

9.07.2025 г., 23:42 ч. UTC

Пазарно говорене

Nikkei May Trade Rangebound as U.S. Tariff Uncertainty Continues -- Market Talk

9.07.2025 г., 22:59 ч. UTC

Пазарно говорене

Reliance Worldwide's Costs at Risk From Copper Tariffs -- Market Talk

9.07.2025 г., 22:59 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

9.07.2025 г., 20:50 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Health Care Roundup: Market Talk

9.07.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

9.07.2025 г., 20:26 ч. UTC

Печалби

Nvidia Is the Most Valuable Company Ever. Why $5 Trillion Could Be Next. -- Barrons.com

9.07.2025 г., 19:18 ч. UTC

Пазарно говорене

Oil Futures End Little Changed After Big U.S. Crude Stock Build -- Market Talk

9.07.2025 г., 19:03 ч. UTC

Пазарно говорене

U.S. Natural Gas Posts Back-to-Back Losses -- Market Talk

9.07.2025 г., 18:31 ч. UTC

Пазарно говорене

Some Fed Officials Supported Considering July Cut -- Market Talk

9.07.2025 г., 17:07 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Honeywell's Streamlining Efforts Clear Path for Stock to Catch Up -- Market Talk

9.07.2025 г., 16:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk -2-

9.07.2025 г., 16:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

9.07.2025 г., 16:20 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Health Care Roundup: Market Talk

9.07.2025 г., 16:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

9.07.2025 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

9.07.2025 г., 16:14 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

9.07.2025 г., 16:14 ч. UTC

Пазарно говорене

Rents in Canada Soften For Ninth-Straight Month -- Market Talk

9.07.2025 г., 16:14 ч. UTC

Придобивния, сливания и поглъщания

Apple Has Dropped the Ball on AI. Buying Perplexity Could Help It Catch Up, Say Analysts. -- Barrons.com

9.07.2025 г., 16:12 ч. UTC

Пазарно говорене

Gold Futures Broadly Flat in Largely Directionless Trade -- Market Talk

9.07.2025 г., 16:08 ч. UTC

Пазарно говорене

Oil Ticks Higher Amid Large U.S. Crude Build, Red Sea Tensions, Tariff Uncertainty -- Market Talk

9.07.2025 г., 15:31 ч. UTC

Значими двигатели на пазара

BitMine Shares Fall After Closing of $250M Private Placement

9.07.2025 г., 15:31 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

With Competing Bids Unlikely, Merck's Path to Acquiring Verona Looks Smooth -- Market Talk

9.07.2025 г., 15:27 ч. UTC

Пазарно говорене

Copper Rally Expected to Fade Amid Tepid Global Demand -- Market Talk

9.07.2025 г., 14:36 ч. UTC

Придобивния, сливания и поглъщания

Merck to Buy Verona Pharma in $10 Billion Deal -- 2nd Update

9.07.2025 г., 14:31 ч. UTC

Придобивния, сливания и поглъщания

Meta Has Surged on the Back of AI Software. Why Hardware Is the Next Play. -- Barrons.com

9.07.2025 г., 14:26 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

9.07.2025 г., 14:26 ч. UTC

Пазарно говорене

Aug 1 Tariffs Will Boost Average Rate Near 15%, JPMorgan Estimates -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

H Lundbeck A-S Прогноза

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно H Lundbeck A-S

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company's principal products include Abilify Maintena/Abilify Maintena for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat MDD and schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat dementia; Onfi for epilepsy; Sabril for the treatment of refractory complex partial seizures and infantile spasms; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol to treat psychosis. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership collaboration with Otsuka Pharmaceuticals Co., Ltd.; and collaboration with Alloy Therapeutics, Inc. for the discovery of novel biologics therapies. The company was founded in 1915 and is headquartered in Valby, Denmark.